Cognition Therapeutics(CGTX) - 2023 Q4 - Annual Results

Cash and cash equivalents as of December 31, 2023, were approximately $29.9 million, and total grant funds remaining from the NIA were$67.5 million. With the additional capital from the March 2024 offering, the Company estimates that it has sufficient cash to fund operations and capital expenditures through May of 2025. Research and development expenses were $37.2 million for the year ended December 31, 2023, compared to$30.3 million for 2022. The increase was primarily related to higher costs associated ...